2Szucs TD.Influenza:the role of burden-of-illness research[J].Pharmacoecono Mics,1999,16(Suppl 1):27-32.
3Bridges CB,Fukuda K,Cox NJ,et al.Prevention and control of influenza:Recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Recomm-Rep,2001,51(RR-3):1-31.
4Keitel WA,Cate TR,Couch R B,et al.Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period[J].Vaccine,1997,15 (10):1114-1122.
2Spila-Alegiani S, Salrnaso S, Rota MC, et al. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine, 1999,17:1898-1904.
3Gerdil C. The annual production cycle for influenza vaccine.Vaccine, 2003,21 : 1776-1779.
4中华人民共和国国家统计局.2003年中国统计年鉴[M].北京:中国统计出版社,2003,9..
5Hayden FG,Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol,1992,176:119-130.
6Whitley RJ,Hayden FG,Reisinger KS,et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J,2001,20:127-133.
7Upshur RE,Knight K,Goel V. Time-series analysis of the relation between influenza virus and hospital admissions of the elderly in Ontario,Canada,for pneumonia,chronic lung disease,and congestive heart failure. Am J Epidemiol,1999,149:85-92.
8Narukawa M,K Minezaki K,Okubo M,et al. Impact of an influenza pandemic on the mortality of congestive heart failure in older Japanese:the 1998 Japanese influenza pandemic. J Am Geriatr Soc,2001,49:689-690.
9Martin C,Mahoney P,Ward P,et al. Oral oseltamivir reduces febrile illness and is safe in patients with chronic cardiac and/or respiratory disease. World Congress on Lung Health,Florence,2000.
10Kaiser L,Wat C,Mills T,et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med,2003,163:1667-1672.
